<DOC>
	<DOCNO>NCT01711333</DOCNO>
	<brief_summary>This study evaluate symptomatic change safety administration Pletaal® SR Capsules base Peripheral Artery Questionnaire ( PAQ ) subject peripheral arterial disease symptom due chronic occlusive arterial disease ( COAD ) .</brief_summary>
	<brief_title>A Multicenter , Therapeutic Used Study Evaluate Efficacy Safety Pletaal SR Capsule ( Cilostazol ) Subjects With Peripheral Arterial Disease Symptom Due Chronic Occlusive Arterial Disease</brief_title>
	<detailed_description>This multinational , single-arm , therapeutic use clinical trial . After screen subject peripheral arterial disease symptom due chronic occlusive arterial disease , eligible subject enrol , follow administration study drug ( two capsule qd Pletaal SR 100mg Capsules ) 12 week .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>1 . Male Female outpatient 40 75 year age , 2 . Patients confirm symptoms peripheral arterial disease ( include intermittent claudication , pain , coldness fatigue ) low extremity , 3 . Patients steady symptom without significant improvement within 12 week prior screen visit whose PAQ score question number 3 3 less enrollment visit , 4 . Ankle Branchial Index ( ABI ) ≤0.90 measuring pressure supine position rest 10 minute , 5 . Patients equal less 10 % difference PAQ summary score screen enrollment , 6 . Patients fully explain study , voluntarily decide participate study , provide write informed consent . 1 . Patients ischemic pain rest ischemic ulcer gangrene , 2 . Patients Ankle Branchial Index ( ABI ) ≤ 0.40 3 . Patients underwent sympathectomy low extremity arterial reparative surgery include endovascular procedure within 12 week prior screen visit , 4 . Patients diagnose deep vein thrombosis within 12 week prior screen visit , ( provided patient isolated calf vein thrombosis may enrol ) 5 . Patients follow disease : Patients need treatment Congestive heart failure Myocardial infarction occur within 24 week prior screen visit Patients need treatment unstable angina pectoris , 6 . Patients hemorrhage ( hemophilia , capillary fragility , intracranial hemorrhage , upper gastrointestinal hemorrhage , urinary hemorrhage , hemoptysis , vitreous hemorrhage , etc . ) predisposition hemorrhage ( active peptic ulcer , hemorrhagic stroke within recent 24 week , suspect hemorrhage administer cilostazol wound due surgery within recent 12 week , proliferative diabetic retinopathy ) , 7 . PT , aPTT level great 1.5 time upper limit normal screen visit , 8 . Uncontrolled hypertension define ≥ 160 mmHg systolic blood pressure ≥ 100 mmHg diastolic blood pressure , 9 . Creatinine clearance ( Ccr ) ≤ 25mL/min screen a. Creatinine clearance ( Ccr ) calculate follow modify CockcroftGault formula use serum creatinine determine site laboratory . Ccr ( mL/min ) = [ 260age ( year ) ] x Body weight ( kg ) / 160 x Serum creatinine ( mg/dL ) ( male ) Ccr ( mL/min ) = [ 236age ( year ) ] x Body weight ( kg ) / 180 x Serum creatinine ( mg/dL ) ( female ) , 10 ) AST ALT level great 3 time upper limit normal screening , 11 ) Total bilirubin level great 2 time upper limit normal screening , 12 ) Type 1 diabetes mellitus uncontrolled type 2 diabetes mellitus ( HbA1c great 9 % ) , 13 ) Patients determine ineligible participate clinical trial discretion Investigator due critical diabetic complication ( diabetic foot ulcer , foot deformity , etc . ) , 14 ) Female patient whose serum pregnancy test screen urine pregnancy test enrollment positive case childbearing potential breastfeeding woman , For female patient , postmenopause least one year longer , potential pregnant surgery procedure , agree use acceptable contraceptive method ( intrauterine device [ loop Mirena ] , double barrier method [ diaphragm condom/femidom + spermicide ] , vasectomy spouse , oral contraceptive nonoral contraceptive ) throughout entire study period , Female patient whose pregnancy test screen positive case childbearing potential breastfeeding woman 15 ) History malignant disease ( exclude treat basal cell squamous cell carcinoma skin ) within 5 year prior Screening . Resolution prior malignancy 5 year prior Screening must deem cured investigator , 16 ) Patients history take plan take following medication : Cilostazolcontaining medication within 12 week prior screen visit , Antiplatelets ( aspirin ticlopidine ) , anticoagulant ( warfarin ) , thrombolytic ( urokinase alteplase ) , prostaglandin E1 derivative ( alprostadil limaprost ) , pentoxyfylline , beraprost , sarpogrelate statin within 4 week prior screen visit . However , aspirin ( ≤ 100 mg ) statin take 4 week prior screen visit may administer dose . Nitrates , papaverine , isoxsuprine , NSAIDs within 4 week prior screen visit . However , NSAIDs take 4 week prior screen visit may administer dose , 17 ) Patients history hypersensitivity cilostazol , 18 ) Patients receive investigational product biological agent within 12 week prior screen visit , 19 ) Patients plan enroll another clinical trial ( exclude observational study ) study , 20 ) Patients need stop Investigational Product schedule operation , extraction tooth endoscopy , 21 ) Patients otherwise judged investigator inappropriate inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>